Viking Therapeutics is developing therapeutics targeting metabolic and endocrine disorders, including obesity, non-alcoholic steatohepatitis (NASH), and X-linked adrenoleukodystrophy (X-ALD). Their pipeline includes specific compounds like VK2735 and VK2809, which aim to improve metabolic health and reduce disease progression in affected patients.
Funding
$632.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metabolic and endocrine disorders, such as obesity, non-alcoholic steatohepatitis (NASH), and X-linked adrenoleukodystrophy (X-ALD), present significant challenges in treatment and disease management. Current therapeutic options may have limited efficacy or undesirable side effects, leaving a need for novel and targeted interventions.
Solution
Viking Therapeutics is focused on developing innovative therapies for metabolic and endocrine disorders. Their pipeline includes a range of compounds designed to address conditions like obesity, NASH/MASH (Metabolic dysfunction-associated steatohepatitis), X-ALD, and other related diseases. These investigational drugs are designed to improve metabolic health, reduce disease progression, and ultimately enhance patient outcomes. The company's approach involves targeting specific pathways and mechanisms implicated in these disorders to achieve greater therapeutic benefit.
Target Audience
The primary target audience includes patients suffering from metabolic and endocrine disorders, as well as healthcare providers specializing in endocrinology, hepatology, and related fields.
Features
- VK2735: A novel therapeutic in development for obesity and metabolic disorders.
- VK2809: A selective thyroid hormone receptor beta (TRβ) agonist being developed for NASH/MASH.
- VK0214: An investigational drug for X-linked adrenoleukodystrophy (X-ALD).
- VK5211: A selective androgen receptor modulator (SARM) previously in development for hip fracture recovery and muscle wasting.
- VK0612: A Phase 2b-ready drug for Type 2 Diabetes.
- VK1430: A drug for Hypertriglyceridemia and NASH.
- EPOR Agonist Program: A program focused on developing treatments for anemia.